Working… Menu
Trial record 53 of 1423 for:    Area Under Curve AND tablet

Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants (Osteopro)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01639222
Recruitment Status : Completed
First Posted : July 12, 2012
Results First Posted : October 18, 2013
Last Update Posted : October 18, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to demonstrate that the intestinal absorption of calcium from a newly developed calcium carbonate-vitamin D3 chewable tablet formulation increases the amount of calcium excreted in urine and decreases parathyroid hormone (PTH) in serum as compared to baseline.

Condition or disease Intervention/treatment Phase
Calcium Deficiency Vitamin D Deficiency Drug: Calcium 500 mg and Vitamin D3 800 IU Other: Low calcium meals Phase 1

Detailed Description:

The drug being tested in this study is called Calcichew. This study will look at calcium absorption in healthy postmenopausal women and healthy men.

The study will enroll approximately 55 healthy adults. All participants will receive Calcichew.

All participants will be asked to take one chewable tablet at the same time each day for three days in period 2 of the trial.

This trial will be conducted at one clinical site in Germany. The overall time to participate in this study is 4 weeks. Participants will make 9 visits to the clinic, and will be contacted by telephone 7days after last dose of study drug for a follow-up assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two Period, One-sequence Open-label Study of a Newly Developed Calcium Carbonate-vitamin D3 Chewable Tablet Formulation (Calcium 500 mg and Vitamin D3 800) Dosed for Three Days to Investigate the Effect on Urine Calcium and Serum Parathyroid Hormone (PTH) as Measurements of Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men Compared to Baseline.
Study Start Date : July 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Calcium 500 mg and Vitamin D3 800 IU

Period 1: Low calcium meals for up to 3 days.

Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals.

Drug: Calcium 500 mg and Vitamin D3 800 IU
Calcium 500 mg and Vitamin D3 800 IU chewable tablets
Other Name: Calcichew-D3 forte 500 mg/800 IU

Other: Low calcium meals
A normal Western European diet with reduced calcium content (400 mg per day).

Primary Outcome Measures :
  1. Amount of Calcium Excreted in Urine From 0 Hours up to 6 Hours Post Dose (Ca2+ Ae0-6h) [ Time Frame: Day 3 of Period 1 (Reference) and Day 3 in Period 2. Samples were taken 0-6 Hours post dose ]
    Ca2+ Ae0-6h was calculated as the urine volume of the urine collected from 0 to 6 hours multiplied by the calcium concentration measured in urine.

  2. Area Under the Curve From 0 to 6 Hours Post Dose of Parathyroid Hormone (PTH AUC0-6h) in Serum [ Time Frame: Day 3 in Period 1 (Reference) and Day 3 in Period 2. Samples were taken at predose, 0.5, 1, 2, 3, 4, and 6 hour post dose. ]
    The area under the curve from 0 to 6 hours post dose of parathyroid hormone (PTH AUC0-6h) in serum, calculated using the linear trapezoidal formula.

Secondary Outcome Measures :
  1. Amount of Calcium Excreted in Urine From 0 to 6 Hours Post Dose Corected for Creatinine (Ae0-6h/Creatinine) [ Time Frame: Day 3 of Period 1 (Baseline) and Day 3 in Period 2. Samples will be taken 0-6 Hours postdose ]
    To account for potential inaccuracies in urine collection, creatinine correction of calcium excretion was also assessed. Ca2+ Ae0-6h/Creatinine was obtained by dividing the urinary concentration of calcium by the urinary creatinine concentration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Is a healthy postmenopausal woman (last menses at least 2 years before signing informed consent and follicle stimulating hormone (FSH) confirming postmenopausal status) or a healthy male aged between 45 to 70 years inclusively
  2. Was informed both verbally and in writing about the objectives of the clinical trial, the methods, the anticipated benefits and potential risks and the discomfort to which she/he might be exposed, and had given written consent to participation in the trial prior to any trial-related procedure
  3. Is Caucasian
  4. Is assessed as healthy based on physical examination, medical history, clinical laboratory, electrocardiogram (ECG), vital signs
  5. Is a non-smoker (having abstained from smoking for at least 6 months)
  6. Has a body mass index of 19 to 29.4 kg/m^2 (inclusively)

Exclusion Criteria:

  1. Has a history of clinically significant allergies or idiosyncrasies to calcium or vitamin D3, or any inactive ingredient(s) of these products
  2. Is a lactating or pregnant female participant
  3. Female participants: Has a positive pregnancy test in serum at screening and in urine on Day -1 Period 1
  4. Participant was previously enrolled into the current clinical trial
  5. Has participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic (PD) effect of the IMP of that clinical trial cannot be excluded (e.g. patient is well into a treatment free safety follow-up phase); or 10 times the pharmacokinetic (PK) half-life, whatever is longer but 30 days as minimum prior to the start of the clinical trial
  6. Has been considered unable or unwilling to co-operate adequately, i.e. to follow clinical trial procedures and Investigator instructions adequately (e.g. language difficulties, etc.) or participant is anticipated not to be available for scheduled clinical trial visits/procedures
  7. Has a dependency situation (e.g. person is kept in detention, Investigator in the current clinical trial, or a first-degree relative of a clinical trial Investigator, or is employee at the clinical trial site)
  8. Has a hypersensitivity to soya or peanut
  9. Abuse of alcohol or drugs
  10. Has consumed ethanol within 48 hours prior to hospitalization verified by alcohol breath test (Alcotest®)
  11. Has a history or current disease which might influence the trial objectives (e.g., urinary tract infection, urination problems [e.g., prostate hyperplasia] or urinary incontinence, renal insufficiency, nephrolithiasis, sarcoidosis, osteoporosis, calcium deficiency, hyper- or hypoparathyroidism, hypercalciuria, hypercalcaemia, calcium lithiasis, hyperphosphataemia, hypervitaminosis D, phenylketonuria, diabetes mellitus
  12. Has creatinine clearance according to Modification of Diet in Renal Disease (MDRD) equation of < 60 mL/min
  13. Has regular use of any medication. Treatment with biphosphonates in the past 5 years, amidorone in the past 6 months, calcium or fluoride supplements, diuretics, vitamin D preparations, estrogens or estrogen receptor modulators, enzyme inducing agents, teriparatide or parathyroid hormone (PTH(1-84)), bile sequestrants within 3 months before screening, and for all other drugs within 2 weeks before screening (or 6 times the half-life of the respective drug) whatever is longer
  14. Has use of ultraviolet radiation cabins or sunbath longer than 1 h from 1 week before Day 1 of Period 1 until the End of Trial examination
  15. Has an intake of milk and milk products, broccoli, dark-green vegetables, vegetables from the mustard green family, fatty fish, eggs, liver, and added salt within 7 days prior to hospitalisation
  16. Has unusual diet habits and practicing vegetarians
  17. Has beverages and food containing poppy seed (i.e. poppy seed rolls, poppy seed cake, milk shakes containing poppy seed) from 72 hours before drug screen to avoid interference
  18. Has chinine, grapefruit- and star fruit-containing beverages and food, St. John's wort (known Cytochrome P450 (CYP450) inhibitors and inducers) within 7 days prior to hospitalization
  19. Has excessive consumption of caffeinated beverages (more than five cups of coffee or equivalent per day)
  20. Has consumption of xanthine-containing beverages and food (e.g. coffee, black and green tea, cola, chocolate) 48 hours prior to hospitalization
  21. Has evidence of acute or chronic hepatitis B or C. Positive test for hepatitis B surface antigen (HBsAg), antibody to the hepatitis B core antigen (anti-HBc) or antibody to the hepatitis C virus (anti-HCV antibody), or human immunodeficiency virus (HIV) infection at screening
  22. Has history of gastrointestinal surgery (except appendectomy) or any other gastrointestinal condition or disease that might influence (calcium) absorption
  23. Has any condition, including laboratory findings or findings in the medical history or screening assessments that, in the opinion of the Investigator, constitutes a specific risk or a contraindication for the participant's participation in the trial or that could interfere with the trial objectives, conduct or evaluation
  24. Has any comedication required during the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01639222

Layout table for location information
Mannheim, Baden-Württemberg, Germany
Sponsors and Collaborators
Layout table for investigator information
Study Director: Principal, Clinical Pharmacology Takeda

Layout table for additonal information
Responsible Party: Takeda Identifier: NCT01639222     History of Changes
Other Study ID Numbers: CW-2200-401-RD
2011-005786-21 ( EudraCT Number )
U1111-1124-2328 ( Registry Identifier: WHO )
First Posted: July 12, 2012    Key Record Dates
Results First Posted: October 18, 2013
Last Update Posted: October 18, 2013
Last Verified: August 2013
Keywords provided by Takeda:
Drug therapy
Increase in calcium urinary excretion and PTH decrease in serum
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Calcium, Dietary
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents